A randomized, double-blind, placebo-controlled 12-week trial of infliximab in patients with juvenile-onset spondyloarthritis

Table 1 Baseline demographics and disease characteristics

	Placebo (n = 14)	Infliximab (n = 12)	p^c
Demographics
Males, no. (%)	13 (92.9)	12 (100.0)	1.000
Age, years mean (SD)	14.5 (2.7)	15.0 (1.7)	0.587
Weight, kg mean (SD)	55.2 (19.5)	52.7 (14.5)	0.718
Body mass index, kg/m² mean (SD)	21.4 (5.1)	19.7 (3.3)	0.339
Radiographic sacroiliitis ^a, no. (%)	2 (14.3)	2 (6.7)	0.763
Disease characteristics
Disease duration, years mean (SD)	6.9 (3.5)	6.4 (2.7)	0.689
HLA-B27, no. (%)	13 (92.9)	10 (90.9)	0.859
Family history of SpA^b, no. (%)	2 (14.3)	1 (8.3)	0.642

no. number, SD standard deviation
^aRadiographic sacroiliitis if at least graded 2 or 3 bilateral or 3 unilateral
^bFamily history of SpA refers to three cases with axSpA, one to nrSpA, and another to rSpA (AS)
^cProbability values of true differences, utilizing parametric t-tests for continuous variables and non-parametric chi-squared tests for nominal variables

ISSN: 1478-6362